The first candidate rotavirus vaccine was a live attenuated oral vaccine made by the classical empirical method of serial passage of virus in tissue culture cells. Current tetravalent vaccine candidates that are in the final stages of efficacy testing in the United States were made by genetic reassortment. This article briefly highlights how advances in the basic understanding of the molecular biology of rotaviruses have facilitated vaccine development. New approaches for second-generation vaccines and improvements in vaccine efficacy based on further exploitation of the tools and knowledge of rotavirus molecular biology and pathogenesis are discussed.
The first candidate rotavirus vaccine was a live attenuated oral vaccine made by the classical empirical method of serial passage of virus in tissue culture cells. Current tetravalent vaccine candidates that are in the final stages of efficacy testing in the United States were made by genetic reassortment. This article briefly highlights how advances in the basic understanding of the molecular biology of rotaviruses have facilitated vaccine development. New approaches for second-generation vaccines and improvements in vaccine efficacy based on further exploitation of the tools and knowledge of rotavirus molecular biology and pathogenesis are discussed.
The ultimate goal of molecular biology is to understand biologic processes in terms of the chemistry and physics of the macromolecules that participate in these processes. Today, molecular biology encompasses the disciplines of cell biology, biochemistry, biophysics, developmental biology, genetics, and structural biology. Herein, I briefly highlight progress toward understanding rotavirus replication and pathogenesis relative to how this basic knowledge has benefitted vaccine development. The first-generation candidate rotavirus vaccines were live attenuated oral vaccines produced by classical virologic techniques. Studies of the molecular biology of rotaviruses were essential to help interpret the results of vaccine trials and to provide other fundamental information that led to the development of multivalent rather than monovalent vaccines. Table 1 presents a time line of notable molecular biology advances relative to the development of rotavirus vaccines that are currently moving toward licensure. The milestones and references are selective, not inclusive, highlights of the advances that have benefitted vaccine development. The impact of these advances is discussed below.
Early Molecular Biology Described the Rotavirus Genome and Proteins
The era of molecular biology for rotaviruses began with a description of the rotavirus genome and its proteins, and provided clues to optimize virus cultivation and identify neutralization antigens. The earliest molecular studies of the rotaviruses involved simple characterization of the genome and the proteins associated with virus particles purified from stool. These studies showed that rotaviruses contain 11 segments of double-stranded (ds) RNA. Conclusions from the initial protein analyses, however, were less clear, primarily because the proteins underwent posttranslational modification (cleavage, glycosylation, and carbohydrate trimming) and because different viruses were studied in different laboratories. A thorough understanding of the molecular properties of the viral proteins (size, posttranslational modification, and location in the viral capsid) required direct studies focused on determining the gene-coding assignments and identification of the functions of the proteins encoded by the genome segments of a single virus strain.
The development of methods to synthesize and purify mRNAs from each dsRNA genome segment, the subsequent translation in cell-free systems, and the comparative analysis of proteins made in these systems with those made in virusinfected cells and those present in different forms of purified virus resolved early confusion. Once the viral proteins were clearly described, molecular analysis of key viral antigens and immunogens could proceed. This was facilitated and complemented by studies in which the biologic properties (hemagglutination, protease-enhanced growth of human viruses, and neutralization antigens) were identified by genetic analysis of single-gene reassortants. Cloning and the subsequent sequence analysis of genes of epidemiologically and serologically diverse virus strains brought the beginnings of an understanding of the molecular basis of the antigenic diversity, transmission, pathogenicity, and evolution of rotaviruses.
Studies of viral proteins led to the recognition that the outer layer of infectious particles contains two proteins, one of which is susceptible to cleavage by proteolytic enzymes (VP4 is cleaved into VP5 and VP8) and the second of which is a glycoprotein (VP7). Figure 1 illustrates features of the virus structure, gene coding assignments, and localization of the viral proteins and antigens. Finding a glycoprotein in the capsid of this nonenveloped virus was surprising initially. However, this finding was better understood once it was recognized that rotaviruses undergo a unique morphogenetic process in which newly made particles become transiently enveloped as they bud into the endoplasmic reticulum of infected cells. Description of this process led to the discovery that the rotaviruses code for a second nonstructural glycoprotein (now called NSP4), and 1958 1969-1972 1973 1974 1975 1976 1977 1978 1977-1979 1977-1979 1979 1980 1980 1980 1980 1981 1981 1981 1980-1983 1980-1981 1982 1982 1982 1983 1983-1987 1983 1983 1984 1984 1985 1985 1985-present 1986-present 1986 1986 1986 1987 1987 1988 1988 1988 1989 1989 1989 1989 1990 1990 1990 1990 1990 1990 1991 1991 1992-1995 NOTE. BRV, bovine rotavirus; HRV, human rotavirus; NA, neutralizing antibody; RRV, rhesus rotavirus; VLPs, virus-like particles.
this nonstructural glycoprotein was found to be important in the unique morphogenetic budding process.
How was this fundamental information relevant to vaccine development? First, because outer capsid viral glycoproteins often are neutralization antigens, the capsid glycoprotein became the focus of studies to determine if antibodies to it had neutralization activity. Second, knowledge that there was a protease-sensitive outer capsid protein stimulated attempts to cultivate the fastidious human rotavirus strains in the presence of proteolytic enzymes. Third, knowledge of the proteins al- . Gene coding assignments and 3-dimensional structures of rotavirus particles. Double-stranded RNA segments separated on polyacrylamide gel (left) code for individual proteins, which are localized in schematic of virus particle (center) or in different protein shells of virus (right). Outer capsid proteins VP4 and VP7 are neutralization antigens, which induce neutralizing antibody; protein that makes up intennediate protein shell, VP6, is subgroup antigen. Binary classification system for rotaviruses refers to P serotypes and G serotypes. Adapted from [116] .
lowed the development of diagnostic assays to detect any rotavirus strain and to determine specific rotavirus serotypes. Fourth, studies pursuing an understanding of the mechanisms that control the unique budding process led to new unexpected results about how rotaviruses cause disease.
Definition of Rotavirus Serotypes and Neutralization Antigens
Cultivation of human rotavirus strains in 1981 led to the recognition that there are different human rotavirus serotypes, which can be distinguished by plaque reduction neutralization assays, and that viruses of human and animal origin may be of the same serotype. In addition, neutralization phenotype was correlated with the viral glycoprotein by studying reassortants, which led to the description of the viral glycoprotein as the major neutralization antigen. Difficulties in obtaining the needed reassortants to study VP4 delayed recognition of the independent role of this protein in neutralization.
Once it was recognized that both outer capsid proteins can induce neutralizing antibody (NA), a binary classification system was proposed, and now serotypes are defined by G (for glycoprotein) type and P (for protease-sensitive) type (figure 1). Three human virus G serotypes were described initially. Genotyping and sequence analysis of the glycoprotein gene showed that genetic results obtained using single gene recombinants correlated with neutralization phenotype. G serotypes were found to be relevant to protective immunity in crossprotection studies in some animal models and in natural infections in children in an orphanage; these data suggested that multivalent vaccines would be needed.
Molecular dissection of the neutralization antigens of a variety of virus strains followed the recognition that different serotypes exist. These studies involved the production of neutralizing monoclonal antibodies (MAbs) and sequence analysis of neutralization escape mutants. The first recognition that the second outer capsid protein, VP4, could induce NAs was obtained with MAbs, and this finding was further confirmed by studies of reassortants. However, focus on the glycoprotein continued because most of the neutralizing MAbs that were first available were to the glycoprotein, and it was perceived to be the major neutralization antigen. Sequence analysis of the glycoprotein gene of viruses in different serotypes revealed regions of sequence variation in distinct serotypes, and generally these same domains contained mutations in neutralization escape mutants. Characterization of mutants made with neutralizing VP7 MAbs, which recognized cross-reactive or typespecific epitopes and discontinuous epitopes, indicated that the glycoprotein contained a single large conformational neutralization domain formed by the interactions of spatially distinct regions of the glycoprotein. Some type-specific and cross-reactive MAbs also were found to induce amino acid substitutions at the same sites, indicating that factors other than the initial binding site likely determined type specificity of some epitopes.
Disulfide bonds and calcium also were shown to be important in maintaining conformational neutralizing epitopes on VP7. Taken together, these data suggested that expression of the glycoprotein using prokaryotic systems might not be feasible to produce biologically active and antigenically native protein capable of inducing NA. This prediction has been borne out by experiments.
Molecular characterization of VP4 was difficult, but typespecific epitopes were localized primarily to the amino terminal VP8 domain, and cross-reactive epitopes were localized to VP5. This mapping agreed with regions of sequence diversity across the gene.
Diagnostic Assays for Serotyping and Molecular Epidemiologic Studies
The development of solid-phase diagnostic assays based on detection of shared cross-reactive proteins of group A rotaviruses was a major advance that led to large-scale epidemiologic studies and documentation of the clinical severity of rotavirus disease. The early ELISAs reported two different reactivities of viruses, and researchers initially thought they were detecting two distinct serotypes of virus. Subsequent studies found that these different reactivities represent distinct epitopes on VP6, the intermediate layer protein, rather than neutralization antigens or serotypes. Subsequent assays using more specific antibodies to the neutralization antigens provided information about serotype distribution.
The MAbs produced to answer basic questions about the epitopes on the structural glycoprotein were adapted to establish rapid ELISAs to permit large-scale epidemiology studies of serotypes. Studies to determine the distribution of G serotypes found at least 14 G serotypes in viruses from animals and humans. Nine G serotypes were characterized in human viruses, and 4 ofthese (serotypes 1-4) have been epidemiologically predominant in most parts of the world during the past 8 years.
Characterization of P types based on neutralization assays has been difficult; therefore, genotyping (because of its simplicity) has been used to study distinct P types. Currently, 20 P types have been identified, 8 of them in human virus strains. In general, the biologic relevance of P genotyping remains unclear, although cross-protective immunity has been induced by particular P types in some animal models. Recent progress in making ELISAs to characterize P types may ultimately resolve the question of how important VP4 is in inducing protective immunity.
Exploitation of Genetic Reassortment to Make Tetravalent Vaccines
When molecular epidemiology studies revealed that multiple serotypes of human rotaviruses exist and when initial vaccine trials with a monovalent vaccine did not protect against a challID 1996; 174 (Suppl 1) lenge of a different serotype, it was thought that multivalent vaccines might be needed. This idea is consistent with many other virus systems in which protection against multiple serotypes is required. The production of multivalent vaccines was accomplished by genetic reassortment, the classical genetic technique used to manipulate the genomes of any segmented RNA virus. While genetic reassortment was useful for manipulating the segmented genomes ofrotaviruses, molecular biology was needed to understand what genes of a donor virus should be inserted into a recipient rotavirus strain to give it the desired characteristics to induce immunity to multiple serotypes of virus. Confirmation that the desired constellation of genes was obtained was made by comparison of the RNA migration patterns on polyacrylamide gels, by hybridization experiments, and by characterization of the antigenic phenotype of the reassortant viruses. The vaccines currently being tested are tetravalent, containing a combination of 3 or 4 different reassortant viruses. In one case, the reassortants are made on a rhesus rotavirus recipient background (providing the serotype G3 antigen), with individual reassortants containing the outer capsid glycoprotein from human rotavirus serotypes G1, G2, and G4. In the second case, a bovine rotavirus (WC3) serves as the recipient for the donated glycoprotein derived from human rotavirus serotypes G 1-4.
Characterization of the Relatedness of Viral Genes by Serotype, Hybridization, Sequencing, and Reverse Transcription -Polymerase Chain Reaction As human and animal rotaviruses were compared, new information emerged about viral genes other than those encoding the neutralization antigens. Hybridization methods to study the relatedness of all the genes among 2 viruses revealed the following: First, 3 major human virus genogroups were identified, and unusual patterns of genetic relatedness between animal and human rotavirus strains were observed, suggesting that transmission of viruses from animals to humans might occur. Second, children with immunodeficiencies were found to become chronically infected with rotaviruses, and virus strains isolated from such children were found to possess unusual genome patterns that result from rearrangements of genetic information within individual RNA segments. These data showed that rotaviruses can evolve by genetic drift (point mutations); genetic shift (segment reassortment), possibly involving transmission of genes from animal viruses; or by genome rearrangements. It is difficult to prove interspecies transmission of viruses; however, the isolation ofviruses containing a bovine VP4 and VP7 from children in India strongly suggests that such transmission can occur. These genes were initially detected only in viruses from cows, and the close association of humans and cows in India might facilitate cross-species transmission. The relative importance of these distinct mechanisms of virus transmission and evolution and how they will influence or be influenced by vaccination programs remains unknown, but monitoring of these mechanisms may prove important.
Structural Studies Bring New Insight into Rotavirus Function
A fresh perspective on rotaviruses came with the first images of the surface structure of rotavirus particles. A new method, electron cryomicroscopy, was developed in 1985 by Dubochet et al. [117] . Application of this technique to the complex rotavirus structure revealed unexpected new information for images at a resolution of '"'-'35 A. The images were striking: Spikes emanated from the surface of particles, and 132 channels were on the surface and penetrated into the particle. These channels are hypothesized to be important for the entry of precursors and exit of the mRNA transcripts, which are made using the endogenous RNA-dependent RNA polymerase that is located in the inner capsid layer and activated by removal of the outer capsid proteins.
Recognition that rotavirus particles contain spikes immediately raised the question of which outer capsid protein is the spike and whether the spike is the viral attachment protein that interacts with the cellular receptor. The spike protein was identified as a dimer of VP4 by pursuing further structural studies using a MAb to this protein. Improvements in the resolution obtainable from structural methods confirmed that the spikes are dimers of VP4 and showed that VP4 not only interacts closely with the surface glycoprotein VP7 but also penetrates through the outer shell and interacts with the trimeric inner capsid protein VP6. Demonstration that these major capsid proteins interact closely was of interest because it provided a structural explanation for unexpected results from studies of the biologic and antigenic properties of some reassortants. Unpredicted phenotypes were observed in reassortants containing specific combinations of the genes that encode VP4, VP6, and VP7, and it had been hypothesized that these unexpected phenotypes resulted from specific combinations of VP4-VP7 or VP4-VP6. Demonstration that VP4 interacts with VP6 provided an explanation for how the spike protein might be assembled onto newly made particles prior to particle budding into the endoplasmic reticulum. In addition, image analysis predicted that the particles are composed of three, rather than two, concentric protein shells. Data obtained from a variety of studies confirmed that particles are triple-layered and that VP6 is a trimer comprising the greatest mass of particle and making up the intermediate protein shell. The stability, mass, and rapid assembly of VP6 on particles explained why this protein is easily detected in clinical samples and why it is so immunogenic.
Expression of Proteins Individually Led to the Discovery of Capsid Protein Self-Assembly and New Approaches for Vaccines and Basic Studies
Expression of rotavirus proteins in eukaryotic insect cells infected with baculovirus recombinants was pursued because key epitopes on the viral glycoprotein were anticipated to require disulfide bonds and other postranslational modifications that would not be achieved in prokaryotes. Expression of VP6 in insect cells infected with a baculovirus recombinant produced encouraging results: The expressed protein folded into oligomers and maintained conformational epitopes. Expression of VP2 showed that this protein self-assembles into a singlelayered protein shell, a result that confirmed biochemically the structural prediction that a third inner shell exists. Coexpression of various combinations of the structural proteins led to the recognition that it is possible to assemble double-layered or triple-layered virus-like particles (VLPs). These VLPs of different protein compositions have shown tremendous potential both as subunit vaccines and for use in further determining the functional properties of individual proteins. Thus, VLPs are highly immunogenic when administered parenterally to animals, including mice, rabbits, and cows, and they have induced active protective immunity in the rabbit model.
VLPs containing different G serotypes have been made, and VLPs containing a G I VP7 have been shown to induce NA to both serotype G I and G3 viruses. In addition, VLPs containing VP4 can bind to cells, but those lacking VP4 do not; this provided the first direct evidence that VP4 is the viral attachment protein. Future biologic and structural studies of VLPs containing various deletion constructs of rotavirus VP4 are expected to help define the functional domains of the spike protein and its sites of interaction with VP7 and VP6. In addition, VLPs have been shown to be active in a new templatedependent RNA replication system, and characterization of the replication phenotype of VLPs lacking VP I or VP3 has indicated that VPI is the viral replicase.
Studies in Animal Models Led to New Understandings of the Immune Response to Rotavirus Infections, Correlates of Protective Immunity, and Virulence Factors
Attempts to analyze correlates of protection in rotavirus vaccine trials in humans have been difficult, possibly because the previous exposure history of vaccinees is not known and most children have some maternally acquired antibody that may interfere with vaccine immunogenicity (determined by a serologic response to the vaccine). Despite many vaccine trials, no correlate of protective immunity based on testing of serum antibodies has been identified. Animal models in which antibody-negative animals could be infected became important in helping to understand the immune response to rotavirus and to dissect what constitutes protective immunity.
Neonatal mice were the first small-animal model studied. Neonates are susceptible to infection and disease up to~14 days of age. This model was useful to study passive immunity, and antibodies to the outer capsid proteins were found to protect against disease following challenge with virulent virus.
The gnotobiotic piglet model was the first large-animal model used to study active immunity, and it continues to be important because it is the only model in which diarrheal disease is induced following inoculation of human rotavirus strains. The gnotobiotic piglet remains important for determining disease responses to human viruses; however its usefulness is limited by its expense, the number of available animals, and the inability to maintain animals in isolators for >8 weeks (thus limiting evaluation because an optimal interval between vaccination and challenge may not be possible).
Adult rabbits were the first small-animal model established to study active immunity. This model is useful because animals are susceptible to challenge for> I year. The adult rabbit model is an infection model: These animals do not get disease following inoculation with virus; instead, infection results in histologic changes in the intestine of infected animals, and infectious virus is shed for 5-6 days after inoculation. This model has shown that the neutralizing response to a single oral virus challenge generally is homotypic, but some virus strains can induce more broadly reactive NA. In addition, studies in rabbits demonstrated that the most sensitive detection of antibody responses requires use of ELISAs with test antigen that closely mimics the challenge virus. These technical points helped optimize test results from human vaccine trials. This model has shown that a single oral inoculation with homologous live virus or two parenteral inoculations with inactivated virus or nonreplicating recombinant VLPs composed of only three or four of the viral capsid proteins can induce active protective immunity, and this immunity correlates with the presence of antibody in the intestine.
The most recent small-animal model established to monitor active immunity to rotavirus infection is the adult mouse model, which also is an infection model. Studies in mice have shown that a single oral inoculation of live virus into antibody-negative mice can induce long-lasting protective immunity, and protection correlates with the presence of intestinal antibody, specifically IgA. One advantage of the mouse model is that recent advances in molecular immunology have resulted in the development of knockout mice, which lack specific arms of the immune system. Study of the immune response in a series of knockout mice confirmed that the presence of intestinal antibody correlates with protective immunity and that cellmediated immunity is important in mediating virus clearance but not protection from infection.
These results provide further support for the idea that a successful vaccine need not be a live replicating vaccine, providing it can induce a potent local antibody response. Studies of the response to homotypic (mouse) or heterotypic (rhesus or rhesus-human virus) reassortants indicated that high doses of heterotypic viruses are required to induce local immunity, and this immune response occurs in the absence of extensive heterotypic virus replication in the intestine. An important remaining question is whether replication occurs and, if so, where do these high doses of live oral heterotypic viruses replicate? If replication occurs extraintestinally, will it pose any danger to children in developing countries who might be malnourished or immunocompromised? This is a relevant question because rotavirus replication has been demonstrated in the liver and kidney of immunocompromised children, and chronic infections are seen in immunocompromised animals and children.
What Genes are Virulence Factors?
Information about what viral genes are virulence factors or host range determinants has emerged from testing virus reassortants with different gene constellations to determine their ability to infect an animal host and cause disease. Early studies in mice infected with heterologous viruses identified the outer capsid proteins as being important in virulence. More recent studies using murine (homologous) viruses in mice identified two nonstructural genes (5 and 7, which code for NSPl and NSP2) as possible host range determinants. Studies in piglets also found that the genes for the outer capsid proteins and gene 3 (the guanylyltransferase) and gene 10 (which codes for NSP4) influenced the ability of a virus to induce diarrhea. Data from cultured cells indicate that the outer capsid proteins are probably important in initiating infection. How genes 3 and 10 might influence virulence remains unknown. The idea that gene 5 might be involved in host range restriction has been supported by the unusual finding that the sequence of this gene is quite similar in viruses isolated from a single species and different among viruses from different species. Gene 5 is an unusual gene because it codes for the nonstructural protein NSP 1 yet it shows an overall significant amount of sequence variation between virus strains isolated from different species. Perhaps an understanding of the function of this gene will lead to construction of more effective vaccine strains.
Basic studies of what controls the viral morphogenetic process in cultured cells recently revealed that the nonstructural glycoprotein and a 22-amino acid synthetic peptide from this glycoprotein can cause diarrhea in mice by acting as a viral enterotoxin. The disease in mice mimics that seen following virus infection in that it is age and dose dependent. Electrophysiology data are consistent with this protein acting as an enterotoxin and thus explain how NSP4 is a virulence factor. These results are exciting because they offer new approaches to prevention of rotavirus-induced diarrheal disease.
Progress toward New Vaccines Based on Parenteral or Orally Administered Nonreplicating Particles
General interest in mucosal immunization stimulated new efforts and ideas about how to optimize delivery of vaccines to protect against infections that replicate on mucosal surfaces. Previously, dogma stated that induction of mucosal immunity required the use of live attenuated vaccines, but this idea is slowly changing. For example, if immunogenicity is affected by the presence of maternal antibody in young children or by interference from concurrent intestinal infections with other pathogens, which may block active viral replication, alternative approaches to induce mucosal antibody may be needed. The challenge in developing the most effective vaccine is to improve the mucosal response so that symptomatic reinfections will not recur. New methods for delivery of nonreplicating vaccines by increasing doses or by delivery ofvirus in microencapsulated or other forms offer the possibility of inducing mucosal immunity to nonreplicating antigens. These new delivery systems may protect the antigen from other interfering substances and directly deliver it to the Peyer's patches for uptake and processing.
Remaining Questions and Ideas about Current and Future Vaccines Stimulated by Molecular Biology Studies
A high priority for vaccine studies in humans is to determine whether intestinal antibody in vaccinees correlates with protection, as it does in animal models. Taken together, the results from studying natural immunity and vaccine-induced immunity in animal models indicate that vaccine trials should be monitoring intestinal antibody relative to protection; surprisingly, this has not yet been done. If this correlate of protection, which has clearly been established in animal models, is not seen in vaccinated children, it will be important to understand why: If there is not a correlation, it may indicate that the method of delivery or the immunogens being used as vaccines need to be optimized further.
Two additional questions are why do immunized children still get diarrhea and why is vaccine efficacy only significant against the most severe disease? This result counters observations from natural infections. The first natural rotavirus infection, which is thought to be the most severe, may not prevent reinfections; however, subsequent severe disease is generally not seen. In addition, several natural infections are thought to induce complete protective immunity. Why then, do two oral doses of live attenuated vaccine not induce significant protection against less severe disease? Improved delivery of current vaccines might enhance vaccine immunogenicity. Current vaccines are administered by giving two oral doses of live attenuated vaccine, but the second dose does not appear to boost immunity; instead, it induces immunity in children who did not respond to the first dose. Does this indicate that the vaccine doses are not optimized or that other methods may be needed to optimize immunogenicity? The following are two of several vaccine possibilities to be tested: first, sequential administration of live oral reassortant vaccines on different donor backgrounds so that antibody induced to VP4 of the donor virus after the first dose does not interfere with boosting at the second dose, and second, initial parenteral administration of a subunit VLP or inactivated vaccine (to induce priming) and subsequent oral administration of live vaccine. Another possibility is that sufficient immunity to NSP4 is not induced by the current vaccines. This idea can be pursued by studying the antibody responses to NSP4 in samples already collected from previous vaccine trials. An alternative approach will be to determine if an NSP4 vaccine can prevent diarrhea. The functions of other gene products that may playa role in host range or virulence (VP3, NSP I, and NSP2) may also be able to be exploited to improve vaccines, but this will require a more detailed understanding of how they function.
Some vaccine trials and studies in animal models have questioned the need for multivalent vaccines, because heterotypic protection can be induced by certain virus strains and heterotypic protection has been observed in the absence of serotypespecific serum NA. A major question that remains untested is whether the current tetravalent vaccines, which do not contain the predominant serotypes found in some developing countries (G6, G8-10, and GI2), will induce protection in persons in those countries. Only 2 serotypes (GI and G3) have been circulating regularly in the areas where tetravalent vaccine efficacy has been tested, so vaccine efficacy against all 4 predominant serotypes is not known, and efficacy is not known in a setting where multiple serotypes are cocirculating. A clear answer about the need for multivalent vaccines may come from vaccine testing in areas where non-G1-4 virus serotypes circulate. Recent data in the adult mouse model also have shown that nonneutralizing IgA antibodies can protect against virus challenge as measured by infection. If similar mechanisms also protect against diarrheal disease, this could explain why serum NA titers are not a clear correlate of vaccine protection but presence of intestinal antibody is.
For at least 10 years, many laboratories have sought to develop a reverse genetics system for rotaviruses. Success with establishing such methods will permit fine mapping of all the rotavirus genes and could lead to the development of new vaccines. It is assumed that understanding the requirements for replication and assembly of the dsRNA segments into particles will provide the keys to gene rescue. The RNA replication process is beginning to be understood from characterization of the proteins associated with replication complexes from infected cells, and recently a template-dependent RNA replication system was established. It is hoped that this new system will be amenable to gene rescue, and this technique will certainly be useful to confirm and further determine how to optimize the balance between rotavirus virulence and immunogenicity. This knowledge should advance the improvement of vaccines.
